Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Finished Goods (2022 - 2025)

Fennec Pharmaceuticals filings provide 4 years of Finished Goods readings, the most recent being $1.6 million for Q4 2025.

  • On a quarterly basis, Finished Goods rose 47.64% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 47.64% increase, with the full-year FY2025 number at $1.6 million, up 47.64% from a year prior.
  • Finished Goods hit $1.6 million in Q4 2025 for Fennec Pharmaceuticals, down from $2.5 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $2.5 million in Q3 2025 to a low of $576000.0 in Q4 2022.
  • Median Finished Goods over the past 4 years was $1.6 million (2025), compared with a mean of $1.6 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 274.31% in 2023 and later tumbled 50.83% in 2024.
  • Fennec Pharmaceuticals' Finished Goods stood at $576000.0 in 2022, then skyrocketed by 274.31% to $2.2 million in 2023, then tumbled by 50.83% to $1.1 million in 2024, then skyrocketed by 47.64% to $1.6 million in 2025.
  • The last three reported values for Finished Goods were $1.6 million (Q4 2025), $2.5 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.